New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 3, 2014
06:17 EDTQCORQuestcor weakness a buying opportunity, says Mizuho
Mizuho said Questcor weakness related to another Citron Research questioning the composition of Acthar based on its own testing is a buying opportunity. The analyst believes there was a label error in testing and that any FDA analysis will come to the same conclusion. Shares are Buy rated with a $93 price target.
News For QCOR From The Last 14 Days
Check below for free stories on QCOR the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
There are no results for QCOR

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use